ClinicalTrials.gg
CompletedNCT01345656ARTSUpdated Feb 10, 2022

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease

A Phase 2 interventional study of BAY94-8862 and BAY94-8862 in Heart Failure, sponsored by Bayer. Completed at 50 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-10.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Enrollment
9th of 23
457 · median 120
Started
2011
the only one that year
Phase 2
5 of 23
2 open now
Registered
1st of 23
by date
Lead sponsor
8 of 23
Bayer

Among the 23 studies testing finerenone in Heart Failure, this one is the 9th largest by enrollment, is the only one that started in 2011, is one of 5 in phase 2, and was the 1st registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

A placebo (Part A) and placebo and active comparator controlled (Part B), double-blind and randomized study to assess safety and tolerability of a new drug (BAY94-8862) given orally

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Chronic Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18 years and older or women aged 55 years and older or women aged 18 years and older without based on surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy
  • Clinical diagnosis of CHF (chronic heart failure), either ischemic or non-ischemic, (New York Heart Association) class II - III, treated with evidenced-based therapy for CHF, e.g. beta-blockers and ACE (angiotensin-converting enzyme) inhibitors or ARB (angiotensin receptor blocker) as well as diuretics, unless or not tolerated
  • Known kidney damage for >/= 3 months, as defined by structural or functional abnormalities of the kidney, and

    • Part A: 60 mL/min/1.73 m*2 \</= (estimated Glomerular Filtration Rate) \< 90 mL/min/1.73 m*2 (MDRD, Modification of Diet in Renal Disease) at the screening visit
    • Part B: 30 mL/min/1.73 m*2 \</= eGFR \<= 60 mL/min/1.73 m*2 (MDRD) at the screening visit
  • Serum potassium \</= 4.8 mmol/L at the screening visit
  • Systolic blood pressure >/= 90 mmHg without signs or symptoms of hypotension at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Known to the study drug (active substance or ) or spironolactone and respective excipients (Part B only)
  • Subjects with anuria, acute renal failure, or Addison's disease
  • Acute coronary syndrome or unstable coronary artery disease within 30 days prior to randomization
  • Valvular heart disease requiring surgical intervention during the course of the study
  • History of hospitalization for hyperkalemia or acute renal failure induced by previous aldosterone antagonist treatment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: BAY94-8862

  • Experimental
    Arm 2

    Drug: BAY94-8862

  • Experimental
    Arm 3

    Drug: BAY94-8862

  • Experimental
    Arm 4

    Drug: BAY94-8862

  • Placebo comparator
    Arm 5

    Drug: Placebo

  • Active comparator
    Arm 6

    Drug: Spironolactone

Interventions

  • Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks

  • Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks

  • One 10 mg BAY94-8862 tablet for duration of 4 weeks

  • Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks

  • DrugPlacebo

    Placebo tablets for duration of 4 weeks

  • Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks

06

What researchers measure

Primary outcomes

  1. Change of serum potassium

    Time frame: 4 weeks

Secondary outcomes

  1. Change in serum magnesium

    Time frame: Day 8, Day 15, Day 22, Day 29

  2. Change in blood pressure

    Time frame: Day 8, Day 15, Day 22, Day 29

  3. Change in heart rate

    Time frame: Day 8, Day 15, Day 22, Day 29

07

Study locations

50 sites
  • Linz, Oberösterreich 4010, Austria
  • Graz, Steiermark 8036, Austria
  • Wien, 1100, Austria
  • Brasschaat, 2930, Belgium
  • Bruxelles - Brussel, 1200, Belgium
  • Roeselare, 8800, Belgium
  • Brno, 625 00, Czechia
  • Liberec, 460 63, Czechia
  • Praha 2, 12808, Czechia
  • Praha 5, 15030, Czechia
  • Copenhagen Ø, 2100, Denmark
  • Esbjerg, 6700, Denmark
  • Frederiksberg, 2000, Denmark
  • Hellerup, 2900, Denmark
  • Herlev, 2730, Denmark
  • Hvidovre, 2650, Denmark
  • København NV, 2400, Denmark
  • Køge, 4600, Denmark
  • Odense, 5000, Denmark
  • Svendborg, 5700, Denmark
  • Viborg, 8800, Denmark
  • Helsinki, FIN-00260, Finland
  • Jyväskylä, FI-40620, Finland
  • Turku, FIN-20520, Finland
  • Frankfurt, Hessen 60596, Germany
  • Köln, Nordrhein-Westfalen 50968, Germany
  • Dresden, Sachsen 01277, Germany
  • Wermsdorf, Sachsen 04779, Germany
  • Wedel, Schleswig-Holstein 22880, Germany
  • Erfurt, Thüringen 99084, Germany
  • Berlin, 13353, Germany
  • Afula, 1834111, Israel
  • Ashkelon, 7830604, Israel
  • Hadera, 3810101, Israel
  • Petah Tikva, 4941492, Israel
  • Rehovot, 7610001, Israel
  • Tel Aviv, 64239, Israel
  • Zefat, 1311001, Israel
  • Oslo, 0450, Norway
  • Stavanger, Norway
  • Krakow, 30-082, Poland
  • Piotrkow Trybunalski, 97-635, Poland
  • Szczecin, 70-965, Poland
  • Warszawa, 04-635, Poland
  • Wroclaw, 50-981, Poland
  • Kristianstad, 29185, Sweden
  • Lund, 222 21, Sweden
  • Stockholm, 111 35, Sweden
  • Stockholm, 118 83, Sweden
  • Stockholm, Sweden
08

References and documents

Publications

  • Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012 Jun;14(6):668-75. doi: 10.1093/eurjhf/hfs061. Epub 2012 May 4. PubMed 22562554 ↗
  • Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27. PubMed 23713082 ↗
  • Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4. PubMed 33107592 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in May 2012, 12 months.

Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2011
First posted
May 2, 2011
StartActual
May 9, 2011
Primary completionActual
May 30, 2012
CompletionActual
Jul 16, 2012
Last update
Feb 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01345656
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 2, 2011
Start date
May 9, 2011
Primary completion
May 30, 2012
Completion
Jul 16, 2012
Last update
Feb 10, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion